JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

ACADIA Pharmaceuticals Inc

Suletud

SektorTervishoid

22.02 1.62

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

21.92

Max

22.18

Põhinäitajad

By Trading Economics

Sissetulek

7.7M

27M

Müük

20M

265M

P/E

Sektori keskmine

15.744

37.461

Kasumimarginaal

10.079

Töötajad

653

EBITDA

21M

40M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+34.47% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

5. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-491M

3.5B

Eelmine avamishind

20.4

Eelmine sulgemishind

22.02

Uudiste sentiment

By Acuity

67%

33%

319 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bullish Evidence

ACADIA Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. okt 2025, 18:41 UTC

Tulu

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24. okt 2025, 18:31 UTC

Tulu

Correction to Procter & Gamble to Focus on Innovation

24. okt 2025, 16:25 UTC

Suurimad hinnamuutused turgudel

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24. okt 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. okt 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24. okt 2025, 21:07 UTC

Tulu

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24. okt 2025, 20:58 UTC

Tulu

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24. okt 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24. okt 2025, 20:40 UTC

Tulu

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24. okt 2025, 20:24 UTC

Tulu

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. okt 2025, 20:23 UTC

Tulu

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. okt 2025, 20:13 UTC

Tulu

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. okt 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24. okt 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24. okt 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24. okt 2025, 19:33 UTC

Tulu

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24. okt 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24. okt 2025, 18:52 UTC

Tulu

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. okt 2025, 18:41 UTC

Tulu

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. okt 2025, 18:03 UTC

Tulu

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24. okt 2025, 18:02 UTC

Tulu

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24. okt 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24. okt 2025, 16:57 UTC

Tulu

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24. okt 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24. okt 2025, 16:44 UTC

Market Talk
Tulu

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24. okt 2025, 16:39 UTC

Market Talk
Tulu

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24. okt 2025, 16:33 UTC

Tulu

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. okt 2025, 16:23 UTC

Tulu

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. okt 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24. okt 2025, 16:07 UTC

Tulu

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

ACADIA Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

34.47% tõus

12 kuu keskmine prognoos

Keskmine 29.61 USD  34.47%

Kõrge 39 USD

Madal 17 USD

Põhineb 19 Wall Streeti analüütiku instrumendi ACADIA Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

19 ratings

13

Osta

5

Hoia

1

Müü

Tehniline skoor

By Trading Central

14.845 / N/AToetus ja vastupanu

Lühikene perspektiiv

Bullish Evidence

Keskpikk perspektiiv

Strong Bearish Evidence

Pikk perspektiiv

Neutral Evidence

Sentiment

By Acuity

319 / 371 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
help-icon Live chat